CVS cites pricing in excluding coverage for Gilead’s HIV drug

Pricing issues have taken precedence as CVS Health’s (NYSE:CVS) pharmacy benefit manager, CVS Caremark, continues to hold off adding Yeztugo, Gilead Sciences’ (NASDAQ:GILD) new HIV prevention drug, to its formularies, Stat News reported on Wednesday. In an email sent to ...